Background: Medullary thyroid carcinoma (MTC) is a neuroendocrine malignancy that frequently metastasizes and has few treatments. This study was aimed at assessing the antitumor effects of suberoyl bishydroxamic acid (SBHA) in an in vivo model of MTC.
Medullary thyroid carcinoma (MTC) is a neuroendocrine (NE) tumor, characterized by its production of NE tumor markers such as calcitonin and chromogranin A (CgA). 1 Although surgery is currently the only effective treatment for MTC, approximately 50% to 80% of patients already have metastatic disease at the time of initial diagnosis, and thus complete surgical resection is often not possible. [2] [3] [4] This emphasizes the need for the development of new treatment strategies.
It has been well established that the occurrence of many cancers are accompanied by a genomewide histone hypoacetylation. 5 In recent years, a great deal of research interest has been focused on efforts aimed at the restoration of the acetylation/deacetylation balance by using histone deacetylase (HDAC) inhibitors, with the hope that a new strategy of cancer treatment can be developed on the basis of this mechanism. 5 Suberoyl bis-hydroxamic acid (SBHA) is a small molecule HDAC inhibitor. Some studies reveal that SBHA exerts antitumor effects by inhibiting acetylation of histone. This results in upregulation of tumor suppressor, proapoptotic, and growth-inhibitory genes in human malignant mesothelioma cells, melanoma cells, and gastrointestinal and pulmonary carcinoid cancer cells. [6] [7] [8] These studies highlight the observation that the inhibiting activity of SBHA on cancer cell growth spans many tissue types, suggesting it could be a useful agent for the treatment of a wide variety of malignancies. Therefore, we sought to investigate whether an in vitro application of SBHA against human MTC cells would lead to growth inhibition. Our findings revealed that SBHA had profound antigrowth activity against MTC cells via caspasedependent apoptosis. 9 In addition, our in vitro data demonstrated that SBHA activates the Notch1 signaling pathway, leading to the reduction of NE tumor markers. 9 These results prompted us to look more closely at the effects of SBHA on MTC cells in vivo. In this study, we used a xenograft model of human MTC to examine whether SBHA activates the Notch1 signaling pathway and inhibits MTC growth in vivo.
PATIENTS AND METHODS

Cell Culture
Human MTC cells (TT) were obtained from American Type Culture Collection (ATCC, Manassas, VA). The TT cell line derived from MEN 2-associated MTC with a RET germ line mutation in codon 634, for alternative mechanisms of tumorigenesis. 10 TT cells maintained in RPMI 1640 (Life Technologies, Rockville, MD) supplemented with 18% fetal bovine serum (Sigma-Aldrich, St. Louis, MO), 100 IU/mL penicillin, and 100 lg/mL streptomycin (Life Technologies) in a humidified atmosphere of 5% CO 2 in air at 37°C.
Xenograft Model and SBHA Administration
Both animal care and treatment were performed in compliance with our animal experiment protocol approved by the University of Wisconsin-Madison Animal Care and Use Committee. Male nude athymic nu/nu mice (Charles Rivers, Wilmington, MD) received subcutaneous injections of TT cells (10 6 ) into the right flank. Mice with palpable tumors were randomly divided into two groups for the study. SBHA (Biomol, Plymouth Meeting, PA) was dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich) at a stock concentration of 500 mg/mL and stored at -20°C. Fresh dilutions in phosphate-buffered saline were made for each injection. The treatment group of mice received 200 mg/kg SBHA every 2 days by intraperitoneal injection for 12 days. A control group was injected with vehicle (DMSO) diluted in phosphatebuffered saline. The mice were weighed three times during the experimental period to assess toxicity of the treatments, and the tumors were measured every 4 days with calipers. Tumor volume was calculated from the two-dimensional caliper measurements with the following formula: tumor volume = [length 9 width 2 9 (p/6)]. On the final day of the study, all mice were killed by carbon dioxide inhalation. The subcutaneous tumor was removed and snap frozen in liquid nitrogen.
Western Blot Analysis
Total tissue proteins were isolated as described, 11 and the protein concentrations were determined with a bicinchoninic assay kit (Pierce, Rockford, IL). Tissue extracts (30-50 lg) were denatured by boiling for 5 minutes and separated by 8%, 10%, or 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were transferred onto nitrocellulose membranes (Schleicher and Schuell, Keene, NH) by electroblotting. Membranes were blocked in milk (5% nonfat dry milk and .1% Tween-20 in phosphatebuffered saline), and exposed to primary and secondary antibodies as described. 9 The following primary antibody dilutions were used: Notch1 (1:1000, Santa Cruz Biotechnology); Achaete Scute Complex Like-1 (ASCL1) (1:1000; BD Pharmingen, San Diego, CA); glyceraldehyde 3 phosphate dehydrogenase (G3PDH) (1:10,000, Trevigen, Gaithersburg, MD); acetyl-histone H 4 (Lys12) (AH 4 ), p21 CIP1/WAF1 , p27 KIP1 , poly (ADP-ribose) polymerase (PARP), cleaved caspase-3, cleaved caspase-9, Bcl-2, Bcl-X L , Bad, Bmf, Bax, cyclin B1, cyclin D1 (1:1000, Cell Signaling Technology, Beverly, MA), and CgA (1:1000, Zymed Laboratories, San Diego, CA). Primary antibody incubations were kept overnight at 4°C, and membranes were washed three times for 5 minutes or three times for 10 minutes in wash buffer (.1% Tween-20 in phosphate-buffered saline). The membranes were incubated with a 1:2000 dilution of horseradish peroxidase-conjugated antimouse secondary antibody (for ASCL1) (Cell Signaling Technology) or anti-rabbit antibody (for Notch1, AH 4 , p21
, p27 KIP1 , PARP, cleaved caspase-3,
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cleaved caspase-9, Bcl-2, Bcl-X L , Bad, Bmf, Bax, cyclin B1, cyclin D1, CgA, and G3PDH). Membranes were developed by Immun-Star (Bio-Rad) for CgA, PARP, Bcl-2, and G3PDH or by Super West Femto chemiluminescence substrate (Pierce) for AH 4 , Notch1, ASCL1, p21 CIP1/WAF1 , p27 KIP1 , cleaved caspase-3, cleaved caspase-9, Bcl-X L , Bad, Bmf, Bax, cyclin B1, and cyclin D1 according to the manufacturers' directions.
Statistical Analysis
Analysis of variance with Bonferroni post hoc testing was performed by SPSS version 10.0 (SPSS, Chicago, IL). A P value of < .05 was considered significant.
RESULTS
SBHA Suppresses Growth of MTC Xenografts in Nude Mice
We have demonstrated that SBHA inhibited the growth of MTC cells in vitro. 9 Thus, we sought to investigate if SBHA could inhibit MTC growth in vivo. Nude mice with MTC tumors received SBHA (200 mg/kg/2 d, intraperitoneal) or DMSO alone for 12 days. Animal weight remained stable over the course of the experiments, and no adverse effects were observed. All animals survived until the respective study endpoints. As shown in Fig. 1 , tumor growth progressively slowed with increasing injections of drug. SBHA-treated animals averaged a 55% inhibition of tumor growth compared with those of DMSO-treated controls (P < .05), which demonstrated that SBHA inhibits MTC growth in vivo.
SBHA Effects of Notch1 Signaling on NE Marker In vivo
The tumors were examined for levels of AH 4 to test the acetylation property of SBHA. Western blot analysis showed that AH 4 statistically significantly increased (Fig. 2) , verifying the activity of SBHA as an HDAC inhibitor in vivo. To provide more evidence for the in vivo efficacy of SBHA, we examined the Notch1 signaling pathway activation and levels of CgA in tumor tissues. Western blot analysis showed that treatment with SBHA resulted in a statistically significantly induction of the active cleaved Notch1 intracellular domain (NICD) (Fig. 3) . Moreover, we found that there was a concomitant decrease in the levels of ASCL1, which is a known downstream target of the Notch1 signaling pathway, indicating that SBHA activates the Notch1 signaling pathway invivo. MTC secretes various bioactive hormones such as CgA. We previously reported that SBHA decreased levels of CgA by inducing Notch1 signaling pathway in MTC cells. 9 In this study, we found a statistically significantly reduction in CgA in SBHAtreated mice (Fig. 3) .
SBHA Induces Cell Cycle Arrest in MTC Xenografts
After establishing that SBHA inhibits MTC growth in vivo, we were interested in determining the mechanism of action for this effect. We have reported 
FIG. 2.
Suberoyl bishydroxamic acid (SBHA) induces accumulation of acetyl-histone H 4 (Lys12) (AH 4 ). Total tumor tissue extracts were isolated from SBHA-treated or dimethyl sulfoxide-treated mice and analyzed for levels of AH 4. Western blot analysis showed that AH 4 is greatly increased in SBHA-treated samples compared with those in the control group. Glyceraldehyde 3 phosphate dehydrogenase (G3PDH) was used to confirm equal protein loading. The quantification of the bands was generated by comparison with G3PDH.
that SBHA induces cell cycle arrest in a variety of carcinoid cancer cell lines by modulating expression of the cyclin-dependent kinase (CDK) inhibitor p21 CIP1/WAF1 and other regulatory proteins. 6 In the present study, we performed Western blot analysis by using MTC xenograft tissue lysates after treatment with SBHA to measure the effects of the drug on cell cycle regulators. Treatment of animals with SBHA resulted in an increase in protein levels of p21 CIP1/ WAF1 and p27 KIP1 (Fig. 4) . To confirm the induction of cell cycle arrest with SBHA treatment, we further examined the levels of cell cycle promoters cyclin B1 and cyclin D1. As expected, SBHA treatment led to a decrease in the levels of these proteins (Fig. 4) , confirming that cell cycle arrest is one of the mechanisms of SBHA induced MTC growth suppression in vivo.
SBHA Regulates the Expression of Apoptotic Mediators and Induces Caspase-Dependent Apoptosis In vivo
It is known that tumor growth suppression is usually due to cell cycle arrest and/or apoptosis. In vitro experiments revealed that SBHA was capable of inducing apoptosis 9 ; therefore, we wanted to determine whether SBHA induces apoptosis in vivo. We carried out Western blot analysis for apoptotic mediators after SBHA treatment. PARP is a wellknown marker of apoptosis, and caspase-3 is the final executioner of both the extrinsic (caspase-8) and intrinsic (caspase-9) apoptotic pathways. 12 As shown in Fig. 5A , apoptotic mediators, including cleavage of PARP, caspase-3, and caspase-9, were detected by Western blot analysis in SBHA-treated animals. We and p27 KIP1 and marked decreases in levels of cyclin B1 and cyclin D1, indicating cell cycle arrest. Glyceraldehyde 3 phosphate dehydrogenase (G3PDH) was used to confirm equal protein loading. The quantification of the bands was generated by comparison with G3PDH.
FIG. 5.
Suberoyl bishydroxamic acid (SBHA) regulates the expression of apoptotic mediators and induces caspase-dependent apoptosis in a mouse model of medullary thyroid carcinoma. Western blot analysis was performed for the levels of apoptotic mediators by using tumor tissue lysates. (A) SBHA treatment resulted in increased caspase-9, caspase-3, and PARP cleavage, indicating activation of the apoptotic pathway. (B) After SBHA treatment, the antiapoptotic proteins Bcl-2 and Bcl-X L were markedly downregulated. In contrast, the expression levels of proapoptotic proteins Bad, Bmf, and Bax were upregulated. Glyceraldehyde 3 phosphate dehydrogenase (G3PDH) was used to confirm equal protein loading.
further evaluated expression of the antiapoptotic and the proapototic proteins in MTC xenograft tumors. Western blot analysis revealed that SBHA downregulated cell survival proteins Bcl-2 and Bcl-X L , but upregulated apoptotic proteins Bax, Bad, and Bmf (Fig. 5B) , confirming that SBHA was capable of inducing apoptosis in vivo. Taken together, Western blot analysis for cell cycle regulatory proteins and apoptotic mediators indicated that SBHA-induced MTC growth inhibition in vivo is due to a combination of cell cycle arrest and apoptosis.
DISCUSSION
Although growth-inhibiting activity of SBHA has been described in a variety of cancer cell lines, [6] [7] [8] [9] there is a scarcity of available data on its ability to inhibit tumor growth in vivo or the mechanisms involved. In this study, we evaluated the effects of SBHA in a nude mouse model of MTC. Our data demonstrated that treatment with SBHA resulted in an average 55% inhibition of tumor growth in the treatment group (P < .05), suggesting that SBHA not only reduced MTC cell viability in vitro, but also had a profound effect on growth of MTC tumors in vivo. During the treatment, these mice had no signs or symptoms of toxicity from the drug. Additionally, we found that the levels of acetylated histones were higher in the tumors developed in nude mice treated with SBHA as compared with control tumor.
Epigenetic modulations of cancer-associated genes have been accepted as key mediators of tumorigenesis, and in particular, these modulations can be controlled by histone acetylation. 13 Therefore, it can be expected that antitumor effects of SBHA in the MTC model involve several genes or signaling transduction pathways. We have previously demonstrated that the Notch1 signaling pathway plays a role in tumor suppression in NE tumors. [14] [15] [16] [17] [18] [19] We found that the global changes of MTC cells from SBHA treatment, especially regarding reduction of the NE tumor markers and growth inhibition, were due to SBHAinducing Notch1 signaling activation, cell cycle inhibitors, or apoptotic mediators. 9 Consistent with the in vitro data, the results from the nude mouse model experiment further supported that SBHA activated the Notch1 signaling pathway as measured by the increase in NICD protein. Notch1 signaling activation by SBHA in vivo also led to a reduction in NE tumor markers such as ASCL1 and CgA.
We recently found by using a doxycycline-inducible NICD construct that overexpression of NICD inhibits MTC cell proliferation, and that this action was mediated by cell cycle arrest associated with upregulation of the CDK inhibitor p21 CIP1/WAF1 . 16 More recently, we reported that apoptosis is also involved in NICD-mediated growth inhibition in SBHA-treated MTC cells. 9 In the present study, we showed that SBHA increased the expression of p21 CIP1/WAF1 and p27 KIP1 and greatly decreased the CDK inhibitors cyclin B1 and cyclin D1 in SBHAtreated mice. We also observed that levels of cleavage of caspase-3 and caspase-9, important effectors of apoptotic cell death, increased in mice treated with SBHA. Proper functioning of cleavage of caspase-3 and caspase-9 was subsequently demonstrated by the detection of one of their cleaved substrates, PARP. Moreover, we found that SBHA downregulated the antiapoptotic protein Bcl-2 and Bcl-X L , but upregulated apoptotic proteins Bax, Bad, and Bmf. Each of these actions was consistent with induction of apoptosis by SBHA in vivo. Taken together, our results indicated that the antitumor effect of SBHA in MTC animal models is due to both cell cycle arrest and apoptosis.
Recently, a phase II trial has been initiated to assess the efficacy and safety of oral suberoylanilide hydroxamic acid (SAHA), a similar drug with SBHA, in patients with recurrent and/or metastatic head and neck cancer. The results of this clinical trial revealed that SAHA administered 400 mg once a day seems to be well tolerated and has modest single-agent activity in those patients. 20 Up to now, almost 40 SAHA clinical trials are being performed for breast cancer, renal cell carcinoma, colon cancer, and other hematologic and solid tumors. 21 In contrast, there has no early clinical data on SBHA in human cancer, although SBHA has in vivo activity with little or no toxicity in the experiment model. Therefore, further clinical trials are needed to evaluate the antitumor activity of SBHA in patients with MTC.
In conclusion, our results demonstrate that the HDAC inhibitor SBHA has impressive antitumor activity in vivo in MTC animal models and a lack of toxicity at doses that effectively inhibit tumor growth. The mechanisms of these effects are due to Notch1 signaling activation, apoptosis induction, and cell cycle arrest. These findings strongly support SBHA as a promising candidate for further preclinical and clinical studies in MTC.
ACKNOWLEDGMENTS
Supported by American Cancer Society Research
Scholars Grant 05-08301TBE; National Institutes of
